A SAD/MAD, Double-Blind, Placebo Controlled, First-In-Human, Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetcs of an NCE asset followed by an Open-label, multi-cohort Part to Assess the Drug-drug Interaction with Rosuvastatin and Metformin in Healthy Males.
Back to Resource Center